Icosapent ethyl: scientific and legal controversies
Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. The product was initially approved by the US Food and Drug Administration for the use of a high dose (4 g/day) in the treatment of hypertriglyceri...
Saved in:
| Main Authors: | Gregory Curfman, Emile Shehada |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-02-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/8/1/e001616.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Similar Items
-
Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl
by: Peter P. Toth, et al.
Published: (2025-03-01) -
Correction to: Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States
Published: (2024-04-01) -
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized Trial
by: Rahul Aggarwal, et al.
Published: (2025-03-01) -
Comparative Risk of Atrial Fibrillation Onset in Statin‐Treated Patients Initiating Icosapent Ethyl and Omega‐3 Acid Ethyl Esters: A Retrospective Cohort Study
by: Jyotirmoy Sarker, et al.
Published: (2025-08-01) -
The Schiavo Decision: Emotional, but Legally Controversial?
by: Lindy Willmott, et al.
Published: (2006-01-01)